An international group of public and private organizations is collaborating to accelerate development of an innovative heat-stable and low-cost, inhaled form of oxytocin to manage postpartum hemorrhage in resource-poor settings.
How does your innovation work?
The technology, originally developed at the Monash Institute of Pharmaceutical Sciences, is being licensed to GSK as part of a coll...
SEE ALLAn international group of public and private organizations is collaborating to accelerate development of an innovative heat-stable and low-cost, inhaled form of oxytocin to manage postpartum hemorrhage in resource-poor settings.
How does your innovation work?
The technology, originally developed at the Monash Institute of Pharmaceutical Sciences, is being licensed to GSK as part of a collaborative agreement to co-develop, register and distribute the product in regions of high maternal mortality.
SEE LESS